SCHEMBL20929469

SCHEMBL20929469

CNc1cnc(C#N)cc1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 3/20 0.40
JAK1 P23458 3/20 0.40
TYK2 P29597 3/20 0.40
JAK3 P52333 3/20 0.40
EGLN2 Q96KS0 3/20 0.38
CHEK1 O14757 7/20 0.35
GABRP O00591 1/20 0.34
GABRD O14764 1/20 0.34
GABRA1 P14867 1/20 0.34
GABRB1 P18505 1/20 0.34
GABRG2 P18507 1/20 0.34
GABRB3 P28472 1/20 0.34
GABRA5 P31644 1/20 0.34
GABRA3 P34903 1/20 0.34
GABRA2 P47869 1/20 0.34
GABRB2 P47870 1/20 0.34
GABRA4 P48169 1/20 0.34
GABRE P78334 1/20 0.34
GABRA6 Q16445 1/20 0.34
GABRG1 Q8N1C3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1643568 0.77 NOS3 (0.44) JAK2JAK1TYK2JAK3EGLN2
SCHEMBL21927619 0.74 EGLN2 (0.41) EGLN2CHEK1GABRPGABRDGABRA1
SCHEMBL153228 0.74 CHEK1 (0.41) JAK2JAK1TYK2JAK3EGLN2
SCHEMBL1746425 0.73 UHRF1 (0.48)
SCHEMBL20917328 0.72 CHEK1 (0.40) EGLN2CHEK1GABRPGABRDGABRA1
SCHEMBL22977515 0.72 CHEK1 (0.40) EGLN2CHEK1GABRPGABRDGABRA1
SCHEMBL16909257 0.72 EGLN2 (0.40) EGLN2CHEK1GABRPGABRDGABRA1
SCHEMBL3107926 0.72 UHRF1 (0.54) JAK2JAK1TYK2JAK3EGLN2
SCHEMBL16909311 0.72 EGLN2 (0.40) JAK2JAK1TYK2JAK3EGLN2
SCHEMBL30944040 0.72 EGLN2 (0.38) JAK2JAK1TYK2JAK3EGLN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4265254-A2 IMIDAZO[4,5-B]PYRIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS Galapagos N.V. (BE) 2023-10-25 EP disclosed
US-20230310433-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS GALAPAGOS NV (BE) 2023-10-05 US disclosed
EP-3697784-B1 IMIDAZO[4,5-B]PYRIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS GALAPAGOS NV (BE) 2023-10-04 EP disclosed
US-11564923-B2 Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders GALAPAGOS NV (BE) 2023-01-31 US disclosed
US-20210169879-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS GILEAD SCIENCES, INC. 2021-06-10 US disclosed
WO-2019076716-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS GALAPAGOS NV (BE) 2019-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210169879-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS IL15, IL2, IL23R JAK2 33/4885JAK1 32/4885TYK2 778/4885
US-11564923-B2 Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders IL15, IL2, IL33 JAK2 29/4885JAK1 36/4885TYK2 905/4885
US-20230310433-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS IL15, IL2, IL33 JAK2 29/4885JAK1 36/4885TYK2 905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.